Arvinas (ARVN) EPS (Diluted) Growth (1y) (2020 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EPS (Diluted) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -11.18% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 96.41% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | 407.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 407.55% |
| Mar 31, 2026 | -178.93% |
| Dec 31, 2025 | -51.55% |
| Sep 30, 2025 | 29.73% |
| Jun 30, 2025 | -71.24% |
| Mar 31, 2025 | 217.81% |
| Dec 31, 2024 | 77.51% |
| Sep 30, 2024 | 42.23% |
| Jun 30, 2024 | 59.96% |
| Mar 31, 2024 | 36.15% |
| Dec 31, 2023 | -85.25% |
| Sep 30, 2023 | 0.73% |
| Jun 30, 2023 | 3.62% |
| Mar 31, 2023 | -31.50% |
| Dec 31, 2022 | -63.30% |
| Sep 30, 2022 | -26.61% |
| Jun 30, 2022 | -23.35% |
| Mar 31, 2022 | -36.65% |
| Dec 31, 2021 | 6.07% |
| Sep 30, 2021 | 0.15% |